FDA Approves Zepbound for Chronic Weight Management, a New Treatment of Obesity or Overweight with Weight-Related Medical Problems

INDIANAPOLIS, Nov. 8, 2023. The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company ' s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials